Title: Surgery and adjuvant dendritic cell-based tumor vaccination for patients with relapsed malignant glioma
Authors: Rutkowski, S
De Vleeschouwer, S
Kaempgen, E
Wolff, JFA
Soerensen, T
Calenbergh, FA
Van Gool, Stefaan
Issue Date: 2004
Publisher: Carden Jennings Pub.
Host Document: Neuro-Oncology vol:6 issue:4 pages:430-431
Conference: 11th International Symposium on Pediatric Neuro-Oncology location:Boston: MA date:JUN 13-16, 2004
Abstract: Patients with relapsed malignant glioma have a poor prognosis. We developed a strategy of vaccination using autologous mature dendritic cells loaded with autologous tumour homogenate. In total, 12 patients with a median age of 36 years (range: 11-78) were treated. All had relapsing malignant glioma. After surgery, vaccines were given at weeks 1 and 3, and later every 4 weeks. A median of 5 (range: 2-7) vaccines was given. There were no serious adverse events except in one patient with gross residual tumour prior to vaccination, who repetitively developed vaccine-related peritumoral oedema. Minor toxicities were recorded in four out of 12 patients. In six patients with postoperative residual tumour, vaccination induced one stable disease during 8 weeks, and one partial response. Two of six patients with complete resection are in CCR for 3 years. Tumour vaccination for patients with relapsed malignant glioma is feasible and likely beneficial for patients with minimal residual tumour burden.
ISSN: 1522-8517
Publication status: published
KU Leuven publication type: IMa
Appears in Collections:Department of Microbiology & Immunology - miscellaneous

Files in This Item:

There are no files associated with this item.


All items in Lirias are protected by copyright, with all rights reserved.